The role of the androgen receptor in triple-negative breast cancer

Women's Health

Volumn 9, Issue 4, 2013, Pages 351-360

  Shah, Payal D ^a,b   Gucalp, Ayca ^a,b   Traina, Tiffany A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Abiraterone acetate; Androgen receptor; Bicalutamide; Enzalutamide; Luminal AR; Triple negative breast cancer

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; BICALUTAMIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENZALUTAMIDE; EXEMESTANE; GONADORELIN DERIVATIVE; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; PACLITAXEL; PLACEBO; PREDNISONE; WNT7B PROTEIN;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; DIMERIZATION; DIZZINESS; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DYSPNEA; ENZYME REGULATION; FATIGUE; FLUSHING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC HETEROGENEITY; HEART PALPITATION; HOT FLUSH; HUMAN; LIGAND BINDING; NAUSEA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; TUMOR XENOGRAFT;

ANDROGEN RECEPTOR ANTAGONISTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; FEMALE; HUMANS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84880379664     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.13.33     Document Type: Review

References (65)

1. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005). (Pubitemid 41464706)
2. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369(9555), 29-36 (2007). (Pubitemid 46039831)
3. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res. 13(15 Pt 1), 4429-4434 (2007). (Pubitemid 47219710)
4. Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple-negative early-stage breast cancer. J. Clin. Oncol. 24(36), 5652-5657 (2006). (Pubitemid 46631305)
5. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26(8), 1275-1281 (2008).
6. Nguyen PL, Taghian AG, Katz MS et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J. Clin. Oncol. 26(14), 2373-2378 (2008).
7. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121(7), 2750-2767 (2011).
8. Brys M. Androgens and androgen receptor: Do they play a role in breast cancer? Med. Sci. Monit. 6(2), 433-438 (2000). (Pubitemid 30313190)
9. Liao DJ, Dickson RB. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J. Steroid. Biochem. Mol. Biol. 80(2), 175-189 (2002). (Pubitemid 34233739)
10. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J. Pathol. 170(1), 31-35 (1993). (Pubitemid 23130581)
11. Park S, Koo J, Park HS et al. Expression of androgen receptors in primary breast cancer. Ann. Oncol. 21(3), 488-492 (2010).
12. Hu R, Dawood S, Holmes MD et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin. Cancer Res. 17(7), 1867-1874 (2011).
13. Moinfar F, Okcu M, Tsybrovskyy O et al. Androgen receptors frequently are expressed in breast carcinomas: Potential relevance to new therapeutic strategies. Cancer 98(4), 703-711 (2003). (Pubitemid 36959265)
14. Ogawa Y, Hai E, Matsumoto K et al. Androgen receptor expression in breast cancer: Relationship with clinicopathological factors and biomarkers. Int. J. Clin. Oncol. 13(5), 431-435 (2008).
15. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: Expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod. Pathol. 23(2), 205-212 (2010).
16. Gucalp A, Tolaney SM, Isakoff SJ et al. Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC). J. Clin. Oncol. 30(Suppl.) Abstract 1006 (2012).
17. Gao W. Androgen receptor as a therapeutic target. Adv. Drug Deliv. Rev. 62(13), 1277-1284 (2010).
18. Friedlander TW, Ryan CJ. Targeting the androgen receptor. Urol. Clin. North Am. 39(4), 453-464 (2012).
19. Sharma NL, Massie CE, Ramos-Montoya A et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 23(1), 35-47 (2013).
20. Weil S, Degen AA, Friedlander M, Rosenstrauch A. Low fertility in aging roosters is related to a high plasma concentration of insulin and low testicular contents of ACTH and lactate. Gen. Comp. Endocrinol. 115(1), 110-115 (1999). (Pubitemid 29321202)
21. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 109(1), 25-32 (2007). (Pubitemid 46120191)
22. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am. J. Clin. Pathol. 120(5), 725-731 (2003). (Pubitemid 37339680)
23. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ. Androgen receptors in breast cancer. Cancer 54(11), 2436-2440 (1984). (Pubitemid 15223385)
24. Peng Y. Potential prognostic tumor biomarkers in triple-negative breast carcinoma. Beijing Da Xue Xue Bao 44(5), 666-672 (2012).
25. Mrklic I, Pogorelic Z, Capkun V, Tomic S. Expression of androgen receptors in triple-negative breast carcinomas. Acta. Histochemica. 115(4), 344-348 (2012).
26. Sutton LM, Cao D, Sarode V et al. Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma. Am. J. Clin. Pathol. 138(4), 511-516 (2012).
27. Park S, Park HS, Koo JS, Yang WI, Kim SI, Park BW. Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers. Breast Cancer Res. Treat. 133(1), 311-320 (2012).
28. Loibl S, Muller BM, von Minckwitz G et al. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res. Treat. 130(2), 477-487 (2011).
29. Park S, Koo JS, Kim MS et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann. Oncol. 22(8), 1755-1762 (2011).
30. He J, Peng R, Yuan Z et al. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: A retrospective analysis based on a tissue microarray. Med. Oncol. 29(2), 406-410 (2012).
31. Yu Q, Niu Y, Liu N et al. Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann. Oncol. 22(6), 1288-1294 (2011).
32. Luo X, Shi YX, Li ZM, Jiang WQ. Expression and clinical significance of androgen receptor in triple-negative breast cancer. Chin. J. Cancer 29(6), 585-590 (2010).
33. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 15(7), 2472-2478 (2009).
34. Soiland H, Korner H, Skaland I et al. Prognostic relevance of androgen receptor detection in operable breast cancer. J. Surg. Oncol. 98(7), 551-558 (2008).
35. Gonzalez LO, Corte MD, Vazquez J et al. Androgen receptor expression in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer 8, 149 (2008).
36. Soreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S. Androgen receptors in operable breast cancer: Relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur. J. Surg. Oncol. 18(2), 112-118 (1992).
37. Koo JS, Jung W, Jeong J. The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast Cancer. Jpn J. Clin. Oncol. 39(9), 560-568 (2009).
38. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann. Intern. Med. 130(4 Pt 1), 270-277 (1999). (Pubitemid 29091854)
39. Hankinson SE, Willett WC, Manson JE et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J. Natl Cancer Inst. 90(17), 1292-1299 (1998). (Pubitemid 28433474)
40. Veronesi U, Pizzocaro G. Breast cancer in women subsequent to cystic disease of the breast. Surg. Gynecol. Obstet. 126(3), 529-532 (1968).
41. Wong YC, Xie B. The role of androgens in mammary carcinogenesis. Ital. J. Anat. Embryol. 106(2 Suppl. 1), 111-125 (2001).
42. Birrell SN, Hall RE, Tilley WD. Role of the androgen receptor in human breast cancer. J. Mammary Gland Biol. Neoplasia. 3(1), 95-103 (1998). (Pubitemid 128513223)
43. Hackenberg R, Schulz KD. Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. J. Steroid. Biochem. Mol. Biol. 56(1-6 Spec No), 113-117 (1996). (Pubitemid 26107886)
44. Goldenberg IS. Testosterone propionate therapy in breast cancer. JAMA 188, 1069-1072 (1964).
45. Goldenberg IS, Sedransk N, Volk H, Segaloff A, Kelley RM, Haines CR. Combined androgen and antimetabolite therapy of advanced female breast cancer. A report of the cooperative breast cancer group. Cancer 36(2), 308-310 (1975).
46. Manni A, Arafah BM, Pearson OH. Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer. Cancer 48(11), 2507-2509 (1981). (Pubitemid 12228016)
47. Dimitrakakis C, Zhou J, Wang J et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 10(4), 292-298 (2003). (Pubitemid 36870501)
48. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J. 14(12), 1725-1730 (2000).
49. Birrell SN, Bentel JM, Hickey TE et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J. Steroid. Biochem. Mol. Biol. 52(5), 459-467 (1995).
50. Garay JP, Karakas B, Abukhdeir AM et al. The growth response to androgen receptor signaling in ERa-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res. 14(1), R27 (2012).
51. Hickey TE, Robinson JL, Carroll JS, Tilley WD. Minireview: The androgen receptor in breast tissues: Growth inhibitor, tumor suppressor, oncogene? Mol. Endocrinol. 26(8), 1252-1267 (2012).
52. Vranic S, Tawfik O, Palazzo J et al. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod. Pathol. 23(5), 644-653 (2010).
53. Ni M, Chen Y, Lim E et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20(1), 119-131 (2011).
54. Doane AS, Danso M, Lal P et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25(28), 3994-4008 (2006). (Pubitemid 43990755)
55. Farmer P, Bonnefoi H, Becette V et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24(29), 4660-4671 (2005). (Pubitemid 41032603)
56. Hall RE, Birrell SN, Tilley WD. Sutherland RL. MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. Eur. J. Cancer. 30A(4), 484-490 (1994). (Pubitemid 24171956)
57. Moore NL, Buchanan G, Harris JM et al. An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocr. Relat. Cancer 19(4), 599-613 (2012).
58. Perrault DJ, Logan DM, Stewart DJ, Bramwell VH, Paterson AH, Eisenhauer EA. Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Invest. New Drugs 6(3), 207-210 (1988).
59. Basu B, Ang JE, Crawley D et al. Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor-(ER) or androgen receptor (AR)-positive advanced breast carcinoma resistant to standard endocrine therapies. J. Clin. Oncol. 29(Suppl.) Abstract 2525 (2011).
60. Cardoso F, Bedard PL, Winer EP et al. International guidelines for management of metastatic breast cancer: Combination vs sequential single-agent chemotherapy. J. Natl Cancer Inst. 101(17), 1174-1181 (2009).
61. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928), 787-790 (2009).
62. Agrawal AK, Jelen M, Grzebieniak Z, Zukrowski P, Rudnicki J, Nienartowicz E. Androgen receptors as a prognostic and predictive factor in breast cancer. Folia Histochem. Cytobiol. 46(3), 269-276 (2008).
63. Bernales S, Guerrero J, Gomez F, Alfaro IE, Protter AA. Effect of MDV3100, a novel androgen receptor signaling inhibitor, on cell proliferation and tumor size in an apocrine breast cancer xenograft model. J. Clin. Oncol. 30(Suppl.) Abstract 3072 (2012).
64. Cochrane D, Bernales S, Jacobsen B et al. Preclinical evaluation of enzalutamide in breast cancer models. Cancer Res. 72(24 Suppl.), P2-14-02 (2012).
65. Li J, Al-Azzawi F. Mechanism of androgen receptor action. Maturitas 63, 142-148 (2009).